Drug Trial Radar · NCT01095640
Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel
Last checked: Nov 19, 2026Latest source record: Mar 30, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,159
Actual
Start
Mar 2009
Primary completion
Dec 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- Actavis Mid-Atlantic LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 30, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Marketed by Galderma Laboratories, L.P., Differin® (adapalene 0.3% topical gel) is a safe and effective topical therapy used for the treatment of acne vulgaris. Actavis Mid-Atlantic LLC has developed a generic formulation of adapalene 0.3% topical gel and the current study is designed to evaluate the safety and efficacy of this formulation.
Conditions
- Acne Vulgaris
Interventions
adapalene 0.3% topical gelDrug
once a day, 84 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Therapeutic EquivalenceTime frame: 12 weeks
- SuperiorityTime frame: 12 Weeks
- SafetyTime frame: 12 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
L.T.M. Medical College & General Hospital
Mumbai, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.